Date: 9/30/2021
Event start time: 12:00 PM
Event end time: 1:00 PM
Category: Webinar
Price: SRT Members: Free **Senior Roundtable Membership Required

Senior Roundtable Webinar:
Exploring The Post-Pandemic IR Landscape: Outreach and Budgeting Considerations for 2022

September 30, 2021
12:00-1:00pm Eastern Time

Exclusive to Senior Roundtable members. Learn more at  

Are you wondering what’s in store for investor outreach and IR activities in 2022?  Join us for a lively discussion, moderated by NIRI Board Chair Ruth Venning, with panelists who will share unique vantage and perspectives on investor and sell-side/corporate access expectations for outreach in 2022.  We will consider: C-suite travel - does it make sense yet for outreach?  Investor Days – in person, virtual or hybrid, safety considerations, prioritizing investors by in person vs virtual contact and the various logistics, as well as other questions.


  • Oliver Dennis, Director, Capital Markets of Strategas Securities, LLC
  • Jorge Gomez, EVP Chief Financial Officer IT & Transformation Office Dentsply Sirona, Inc.
  • Annabel Samimy, Managing Director and Senior Analyst in Healthcare, covering Biopharmaceuticals at Stifel
  • Ian Somaiya, Chief Financial Officer at TCR2
  • Ruth Venning, Executive Director, Investor Relations at Horizon Therapeutics plc (moderator)

Bonus 30-minute chat session:

Want to discuss the program afterward with your peers? Join us for an optional networking session just amongst SRT peers immediately afterward. Access details will be provided in your registration confirmation.

IRC® credential holders can earn 1 professional development unit (PDU). Learn more at

Oliver Dennis is a Director of Capital Markets at Strategas Securities, a leading institutional brokerage firm focused on providing macro research, advisory and capital market services to institutional investors and corporate executives around the world.

In his current role, Oliver originates and sources Equity and Debt Capital Market relationships. Additionally, he co-manages Strategas’ Corporate Access Platform for executive management and investor relations officers. He works with public companies across the market cap scale in various sectors, connecting them with institutional investors in underserved investment centers throughout the United States and Canada.

Prior to joining Strategas, Mr. Dennis worked as a Client Associate at Merrill Lynch Wealth Management where he was responsible for extensive client contact and all activities that touch prospective and existing clients for a team of two senior financial advisors.

He holds a B.A. degree from St. Lawrence University and is an active volunteer firefighter for the New Canaan Fire Department.

Jorge Gomez has served as Executive Vice President & Chief Financial Officer of Dentsply Sirona, Inc. since August 2019.  Dentsply Sirona is the largest manufacturer of professional dental products and technologies including, software and workflow solutions, serving customers in more than 120 countries.

Mr. Gomez is responsible for leading Dentsply Sirona’s global finance organization including strategic finance, FP&A, Accounting, Treasury, Tax, Corporate Audit, and Investor Relations.  In addition, he is responsible for the Information Technology function. Mr. Gomez also leads “Beyond”, the company’s sustainability and ESG program.

Prior to Dentsply Sirona, Mr. Gomez was Chief Financial Officer of Cardinal Health Inc., a Fortune 14 company. He joined Cardinal Health in 2006 where he held other positions including Medical Segment CFO, Pharmaceutical Segment CFO, Corporate Treasurer and Corporate Controller before being appointed Chief Financial Officer.

Earlier in his career, Mr. Gomez held financial and business leadership positions of progressive responsibility at General Motors Corp., including posts in New York City, Singapore, Belgium, and Brazil. He began his career with Jefferson Smurfit in their finance development program after earning a Bachelor of Science degree in Electrical Engineering from the National University of Colombia and a Master of Business Administration from the University of Hartford.
Mr. Gomez currently serves as a member of the Boards of Directors for Xylem, Inc and Pear Holdings Corporation.  Xylem is a leading global water technology provider, serving customers in more than 150 countries with innovative solutions to their most complex water challenges.  Pear Holdings Corp. is the leader in developing and commercializing prescription digital therapeutics to treat serious disease.

Annabel Samimy joined Stifel in 2010. Based out of the New York office, Ms. Samimy is a Managing Director and Senior Analyst in Healthcare, covering Biopharmaceuticals.

Prior to joining Stifel, Ms. Samimy was an analyst with Thomas Weisel Partners covering Specialty Pharmaceuticals, as well as UBS covering small/mid-cap Pharmaceutical and Biotechnology companies. Her past awards include the Wall Street Journal’s “Best on the Street” Analysts Survey (2009), and she has ranked three times in FT/StarMine—twice as #2 for Earnings Estimates (2014, 2019) and #3 for Stock Picker (2016). Before entering equity research, Ms. Samimy was an associate in the Structured/Project finance group at UBS.

Ms. Samimy is a graduate of Tufts University, where she studied International Relations/Economics, and earned a Masters from Columbia University/SIPA where she studied International Finance and Business

Ian Somaiya joined TCR2 in 2018 as Chief Financial Officer. He brings more than 20 years of experience in finance and healthcare as a equity research analyst on Wall Street. Prior to joining TCR2, Mr. Somaiya was Managing Director and Head of Biotechnology Research at BMO Capital Markets. During his 20-year career, Mr. Somaiya conducted extensive research on more than 100 biotechnology companies across diverse therapeutic areas, technology platforms and stages of development. Previously, he served as a Managing Director and Equity Analyst at Nomura Securities Co. Ltd., Piper Jaffray Companies and Thomas Weisel Partners Group, Inc. He launched his Wall Street career as a research analyst at Morgan Stanley and Prudential Securities, and was recognized as the "Best on the Street" by The Wall Street Journal for his coverage on biotechnology in 2006, 2007 and 2009. Mr. Somaiya received his Bachelor of Arts degree in Biology and Neuroscience from New York University.

Ruth Venning is executive director of investor relations for Horizon Therapeutics plc, a $22 billion market cap biopharmaceutical company specializing in medicines for rare diseases.  Working closely with the investment community and Horizon leaders, Venning is integrally involved with day-to-day communication with the investment community, IR strategic planning and messaging, analytics and investor communications.  In addition, she drives Horizon Pharma’s governance outreach, is responsible for Company’s proxy statement and is integrally involved in Horizon’s ESG disclosure initiatives, in addition to coordinating the development of investor-relations communications and IR activities

Venning has deep experience across several industries in investor relations, corporate communications and crisis management.  Prior to joining Horizon Therapeutics in May 2017, she served as director of investor relations for Hospira, Inc., a generic injectable pharmaceutical and medical device company acquired by Pfizer.  During her 10 years with Hospira, Venning was responsible for day-to-day communication with the investment community, as well as institutional targeting, proxy outreach, retail shareholder relations, and the production of the annual report and other investor materials.  She launched the company’s proxy outreach program in 2010 and spearheaded Hospira’s adoption of the notice-and-access distribution model in 2009, ahead of the adoption curve for practices that now are standard in investor relations.

Before joining Hospira, Venning was director of corporate relations for Telephone and Data Systems, Inc., where she managed corporate communications and investor relations.  Prior to that, she served United Airlines for five years in financial communications and investor relations roles.  Earlier, she directed corporate communications for Calamos Asset Management, a Chicago-area investment management firm.  Venning began her career in international public relations, working primarily for the Japanese government in Japan.

Venning holds an MBA in finance from Lake Forest Graduate School of Management, a master’s degree in corporate communications from Northwestern University, and a bachelor’s degree in Japanese studies from Earlham College.  She is an adjunct instructor in Northwestern University’s Integrated Marketing Communications graduate program.

Venning has served on the NIRI Board of Directors since 2018 and as Chair of the Board since December 2020.  Also active on a chapter level,  Venning has served on the NIRI-Chicago board of directors since 2004, including as the board’s president in 2007 and chairman in 2008. She is also a member of the National Association of Corporate Directors (NACD) and Women in Bio.